Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Croydon, United Kingdom Clinical Trials

A listing of Croydon, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (76) clinical trials

A FIH Study to Investigate the Safety Tolerability and PK of P218

The study is divided into two parts: Part A This is a double-blind randomised, placebo-controlled, parallel group, ascending dose study and will comprise up to eight fasted cohorts (8 volunteers in each) that will receive a single ascending dose (SAD) of P218 to assess its safety, tolerability and pharmacokinetic profile. ...

Phase

1.0 miles

Learn More »

A Study to Assess the Safety Tolerability Pharmacokinetics Immunogenicity and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

The primary purpose of this study is to assess the safety and tolerability of JNJ-64179375 in Part 1 and 2.

Phase

1.08 miles

Learn More »

A Study of TAS-116 in Patients With Solid Tumors

A First-in-Human (FIH) study of TAS-116 in patients with advanced solid tumors was first initiated in Japan in April 2014 and has been ongoing since then. The study consists of a dose escalation phase and a dose expansion phase. Three dosing regimens of TAS-116, once daily (QD), every other day ...

Phase

2.93 miles

Learn More »

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Cancer cells can have different kinds of proteins on their cell surface; one of these is the protein HER2. HER2 plays an important role in the development of cancer. High expression of HER2 is related to poor prognosis. Although several cancer drugs are available that work via the HER2 protein, ...

Phase

4.25 miles

Learn More »

An Open-Label Study of the Safety Tolerability and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW) in subjects with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, gemcitabine, and cisplatin to determine the safety ...

Phase

4.25 miles

Learn More »

Study of E7386 in Subjects With Selected Advanced Neoplasms

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

Phase

4.25 miles

Learn More »

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

OBJECTIVES Primary To determine whether olaparib crosses the blood-brain barrier (BBB) and achieves tumor penetration in patients with relapsed glioblastoma. (Stage 1) To determine the safety and tolerability of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2) Secondary To assess BBB disruption and BBB permeability ...

Phase

4.25 miles

Learn More »

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

The purpose of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).

Phase

4.25 miles

Learn More »

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer

Risk and burden for patients Patients in this study have cancer that often proves hard to control with standard care. The early phase nature of this study means that the intervention may not have any benefit for patients who take part in the study. However, they will still receive the ...

Phase

4.57 miles

Learn More »

The study will be divided into two parts: a "dose-escalation part" to evaluate safety profile and to explore the Maximum tolerated dose (MTD) and an "expansion part" to evaluate further the safety and tumor response profile of BAY1862864 Injection at the selected dose.

Phase

4.57 miles

Learn More »